SI20511B - Izdelovanje trenutno raztopljivega peroralnega odmerka - Google Patents
Izdelovanje trenutno raztopljivega peroralnega odmerka Download PDFInfo
- Publication number
- SI20511B SI20511B SI200000187A SI200000187A SI20511B SI 20511 B SI20511 B SI 20511B SI 200000187 A SI200000187 A SI 200000187A SI 200000187 A SI200000187 A SI 200000187A SI 20511 B SI20511 B SI 20511B
- Authority
- SI
- Slovenia
- Prior art keywords
- calcium silicate
- dosage form
- currently
- pharmaceutical dosage
- density
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000008187 granular material Substances 0.000 claims abstract 11
- 239000003795 chemical substances by application Substances 0.000 claims abstract 7
- 239000003814 drug Substances 0.000 claims abstract 7
- 239000011230 binding agent Substances 0.000 claims abstract 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 5
- 238000000034 method Methods 0.000 claims abstract 3
- 239000006185 dispersion Substances 0.000 claims abstract 2
- 238000009826 distribution Methods 0.000 claims abstract 2
- 239000000378 calcium silicate Substances 0.000 claims 26
- 229910052918 calcium silicate Inorganic materials 0.000 claims 26
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 claims 26
- 239000002552 dosage form Substances 0.000 claims 23
- 239000000203 mixture Substances 0.000 claims 7
- 239000007884 disintegrant Substances 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 3
- 238000000465 moulding Methods 0.000 claims 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 2
- 229910021486 amorphous silicon dioxide Inorganic materials 0.000 claims 2
- 229960000913 crospovidone Drugs 0.000 claims 2
- 238000007580 dry-mixing Methods 0.000 claims 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 2
- 238000003825 pressing Methods 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 239000005995 Aluminium silicate Substances 0.000 claims 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 239000005909 Kieselgur Substances 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229920000881 Modified starch Polymers 0.000 claims 1
- 235000012211 aluminium silicate Nutrition 0.000 claims 1
- UWFFNDSXSPUNTR-UHFFFAOYSA-N aluminum magnesium silicic acid trihydroxy(oxido)silane silicate Chemical compound [Mg+2].[Al+3].O[Si](O)(O)O.O[Si](O)(O)[O-].[O-][Si]([O-])([O-])[O-] UWFFNDSXSPUNTR-UHFFFAOYSA-N 0.000 claims 1
- 229960004372 aripiprazole Drugs 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- 235000011010 calcium phosphates Nutrition 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 230000006835 compression Effects 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 238000007907 direct compression Methods 0.000 claims 1
- 239000002270 dispersing agent Substances 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 230000001698 pyrogenic effect Effects 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract 2
- 239000000654 additive Substances 0.000 abstract 1
- 235000003599 food sweetener Nutrition 0.000 abstract 1
- 239000006187 pill Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000003765 sweetening agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Podan je postopek priprave zrnc za izdelavo trenutno raztopljivih peroralnih farmacevtskih dozirnih oblik. Poleg enega ali večih zdravil, so zrnca sestavljena iz ekscipientne kombinacije, ki sestoji iz superdisintegranta, disperznega sredstva, distribucijskega oz. porazdelitvenega sredstva ter vezivnega sredstva. Prav tako vključujejo konvencionalne dodatke oz. primesi, kot so sladila in arome. Zrnca, ki so predmet obravnavanja, imajo to prednost, da so stabilna in da so lahko izdelana brez dodatka topil ne da bi bilo pri tem potrebno posebno okolje ali rokovanje. Dozirne oblike, posebno tablete, ki so iz njih izdelane na konvencionalni opremi, se razkrojijo v ustih v manj kot približno petindvajsetih sekundah.
Claims (23)
- -1 - Sl 20511 FORMULACIJA TRENUTNO RAZTOPLJIVEGA PERORALNEGA ODMERKA PATENTNI ZAHTEVKI 1. Trenutno raztopljiva farmacevtska dozirna oblika, ki se bo razkrojila v ustih v manj kot 25 sekundah, obsegajoča zdravilo in kombinacijo ekscipientov, ki obsega, na osnovi celotne mase dozirne oblike, a) od 4 do 8 % (masni delež) super-razgrajevalca, b) od 20 do 70 % (masni delež) disperzijskega sredstva, ki je kalcijev silikat, c) od 1 do 10 % (masni delež) porazdelitvenega sredstva, izbranega iz amorfnega silicijevega dioksida, pirogenega silicijevega dioksida, diatomejske zemlje, smukca, kaolina in magnezijvega aluminijevega trisilikata in d) od 10 do 50 % (masni delež) veziva.
- 2. Trenutno raztopljiva farmacevtska dozirna oblika po zahtevku 1, ki obsega ne več kot 30 procentov (masni delež) zdravila in ne več kot 85 procentov (masni delež) skupne vsote kombinacije ekscipientov.
- 3. Trenutno raztopljiva farmacevtska dozirna oblika po zahtevku 2, ki obsega, na osnovi celotne mase omenjene dozirne oblike, ne več kot okoli 30 procentov (masni delež) omenjenega zdravila, od 5 do 7 procentov (masni delež) omenjenega super-razgrajevalca, od 35 do 45 procentov (masni delež) omenjenega disperzijskega sredstva, od 1,5 do 3 procente (masni delež) omenjenega porazdelitvenega sredstva in od 12 do 20 procentov (masni delež) omenjenega veziva.
- 4. Trenutno raztopljiva farmacevtska dozirna oblika po katerem koli od predhodnih zahtevkov, pri čemer je kalcijev silikat izbran iz orto, meta in alfa triklinskega kalcijevega silikata.
- 5. Trenutno raztopljiva farmacevtska dozirna oblika po zahtevku 4, pri čemer je omenjeni kalcijev siilkat alfa triklinski kalcijev silikat. -2-
- 6. Trenutno raztopljiva farmacevtska dozirna oblika po katerem koli od predhodnih zahtevkov, pri čemer je omenjeni super-razgrajevalec krospovidon, natrijeva kroskarmeloza, natrijev škrobni glikolat, nizko substituirana hidroksipropil celuloza ali predželatiniran škrob in omenjeno vezivo je mikrokristalna celuloza, hidroksipropil celuloza, etil celuloza, laktoza, manitol ali kalcijev fosfat.
- 7. Trenutno raztopljiva farmacevtska dozirna oblika po zahtevku 1, pri čemer je omenjeni super-razgrajevalec krospovidon, omenjeni kalcijev silikat je kristalni alfa triklinski kalcijev silikat, omenjeno porazdelitveno sredstvo je amorfni silicijev dioksid in omenjeno vezivo je mikrokristalna celuloza.
- 8. Trenutno raztopljiva farmacevtska dozirna oblika po katerem koli od zahtevkov 1 do 3, pri čemer je omenjeni kalcijev silikat sestavljen iz kombinacije alfa triklinskega kalcijevega silikata in vsaj ene druge farmacevtske vrste kalcijevega silikata, pri čemer omenjeni alfa triklinski kalcijev silikat obsega od 10 % do 90 % (masni delež) omenjene kombinacije.
- 9. Trenutno raztopljiva farmacevtska dozirna oblika po katerem koli od zahtevkov 1 do 4, pri čemer ima omenjeni kalcijev silikat površino 1,0 m2/g (m2/gm) do 210 m2/g (m2/gm), nasipno gostoto 0,075 g/ml_ (g/cc) do 0,90 g/mL (g/cc), pravo gostoto 1,70 g/mL (g/cc) do 2,90 g/mL (g/cc) in vsebnost hlapnih snovi manj kot 1 % do 14 % m/m.
- 10. Trenutno raztopljiva farmacevtska dozirna oblika po zahtevku 9, pri čemer je omenjeni kalcijev silikat alfa triklinski kalcijev silikat, ki ima površino 1,3 m2/g (m2/gm), nasipno gostoto 0,627g/mL (g/cc), pravo gostoto 2,934 g/mL (g/cc) in vsebnost hlapnih snovi 0,5 % m/m.
- 11. Trenutno raztopljiva farmacevtska dozirna oblika po zahtevku 9, pri čemer je omenjeni kalcijev silikat orto kristalen kalcijev silikat, ki ima površino 0,98 m2/g (m2/gm), nasipno gostoto 0,492 g/mL (g/cc), pravo gostoto 3,252 g/mL (g/cc) in vsebnost hlapnih snovi 0,02 % m/m.
- 12. Trenutno raztopljiva farmacevtska dozirna oblika po zahtevku 9, pri čemer je omenjeni kalcijev silikat meta kristalen kalcijev silikat, ki ima površino 2,5 m2/g (m2/gm), nasipno gostoto 0,867 g/mL (g/cc), pravo gostoto 2,940 g/mL (g/cc) in vsebnost hlapnih snovi 0,5 % m/m. -3-
- 13. Trenutno raztopljiva farmacevtska dozirna oblika po zahtevku 9, pri čemer je omenjeni kalcijev silikat kristalen kalcijev silikat, ki ima površino 90,4 m2/g (m2/gm), nasipno gostoto 0,094 g/ml_ (g/cc), pravo gostoto 2,598 g/mL (g/cc) in vsebnost hlapnih snovi 0,94 % m/m.
- 14. Trenutno raztopljiva farmacevtska dozirna oblika po zahtevku 9, pri čemer je omenjeni kalcijev silikat amorfni kalcijev silikat, ki ima površino 191,3 m2/g (m2/gm), nasipno gostoto 0,120 g/mL (g/cc), pravo gostoto 2,314 g/mL (g/cc) in vsebnost hlapnih snovi 5,11 % m/m.
- 15. Trenutno raztopljiva farmacevtska dozirna oblika po zahtevku 9, pri čemer je omenjeni kalcijev silikat amorfni kalcijev silikat, ki ima površino 103,0 m2/g (m2/gm), nasipno gostoto 0,130 g/mL (g/cc), pravo gostoto 1,702 g/mL (g/cc) in vsebnost hlapnih snovi 9,90 % m/m.
- 16. Trenutno raztopljiva farmacevtska dozirna oblika po zahtevku 9, pri čemer je omenjeni kalcijev silikat amorfni kalcijev silikat, ki ima površino 209 m2/g (m2/gm), nasipno gostoto 0,075 g/mL (g/cc), pravo gostoto 2,035 g/mL (g/cc) in vsebnost hlapnih snovi 13,8 % m/m.
- 17. Trenutno raztopljiva farmacevtska dozirna oblika po katerem koli od predhodnih zahtevkov, pri čemer je omenjeno zdravilo aripiprazol.
- 18. Trenutno raztopljiva farmacevtska dozirna oblika po katerem koli od predhodnih zahtevkov, ki je tableta.
- 19. Trenutno raztopljiva farmacevtska dozirna oblika po zahtevku 1, ki se da dobiti s suhim mešanjem zdravila in kombinacije ekscipientov, kot je definirano v katerem koli od zahtevkov 1 do 18, v zmes, s stiskanjem zmesi skozi primeren kompaktor ali oblikovalno napravo, da nastanejo kompaktirani deli ali oblikovanci in s prehajanjem kompaktiranih delov ali oblikovancev skozi sito, da nastanejo zrnca.
- 20. Trenutno raztopljiva farmacevtska dozirna oblika po zahtevku 19, ki se da dobiti z nadaljnjim stiskanjem zrnc. -4-
- 21. Postopek oblikovanja zrnc, primernih za stiskanje v trenutno raztopljive dozirne oblike, po katerem koli od zahtevkov 1 do 20, ki obsega suho mešanje zdravila in kombinacije ekscipientov, kot je definirano v katerem koli od zahtevkov 1 do 20, v zmes, s stiskanjem zmesi skozi primeren kompaktor ali oblikovalno napravo, da nastanejo kompaktirani deli ali oblikovanci in s prehajanjem kompaktiranih delov ali oblikovancev skozi sito, da nastanejo zrnca.
- 22. Postopek oblikovanja zrnc po zahtevku 21, ki dodatno obsega stopnjo mešanja omenjenih zrnc z dodatnimi količinami omenjenega super-razgrajevalca in veziva, da nastane končna zmes, primerna za direktno stiskanje v omenjene tablete.
- 23. Postopek po zahtevku 22, pri čemer omenjena zrnca obsegajo od okoli 80 % do okoli 99 % (masni delež) omenjene končne zmesi.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54794800A | 2000-04-12 | 2000-04-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SI20511A SI20511A (sl) | 2001-10-31 |
| SI20511B true SI20511B (sl) | 2008-08-31 |
Family
ID=24186805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200000187A SI20511B (sl) | 2000-04-12 | 2000-08-14 | Izdelovanje trenutno raztopljivega peroralnega odmerka |
Country Status (43)
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19820801A1 (de) * | 1998-05-09 | 1999-11-25 | Gruenenthal Gmbh | Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten |
| CA2311734C (en) * | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
| US20020076437A1 (en) | 2000-04-12 | 2002-06-20 | Sanjeev Kothari | Flashmelt oral dosage formulation |
| US7053092B2 (en) | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
| BR0207297A (pt) | 2001-02-15 | 2005-04-19 | King Pharmaceuticals Inc | Composição farmacêutica em forma sólida e método de preparar uma forma de dosagem sólida de um ingrediente farmaceuticamente ativo |
| US6555581B1 (en) | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
| MY129350A (en) * | 2001-04-25 | 2007-03-30 | Bristol Myers Squibb Co | Aripiprazole oral solution |
| US7101569B2 (en) | 2001-08-14 | 2006-09-05 | Franz G Andrew | Methods of administering levothyroxine pharmaceutical compositions |
| MY138669A (en) * | 2001-09-25 | 2009-07-31 | Otsuka Pharma Co Ltd | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
| BR0117147A (pt) * | 2001-10-09 | 2006-05-09 | Bristol Myers Squibb Co | preparado de dosagem oral de desintegração instantánea |
| US6610266B2 (en) * | 2001-11-28 | 2003-08-26 | Michael C. Withiam | Calcium metasilicates and methods for making |
| AU2002346694A1 (en) * | 2001-12-10 | 2003-06-23 | Dr. Reddy's Laboratories Ltd. | Amorphous form of 2-n-butyl-3-( (2-(1h-tetrazol-5-yl) (1,1'-biphenyl)-4-yl) methyl) -1,3-diazaspiro (4,4') non-1-en-4-one |
| CN1638803A (zh) * | 2002-03-06 | 2005-07-13 | 协和发酵工业株式会社 | 口腔内速崩解性片剂 |
| AU2003238670A1 (en) * | 2002-04-05 | 2003-10-27 | Cadila Healthcare Limited | Fast disintegrating oral dosage forms |
| MY131488A (en) * | 2002-04-08 | 2007-08-30 | Bristol Myers Squibb Co | Low dose liquid entecavir formulations and use |
| GEP20063996B (en) | 2002-08-20 | 2006-12-11 | Bristol Myers Squibb Co | Aripiprazole complex formulation and use thereof |
| DE10247037A1 (de) * | 2002-10-09 | 2004-04-22 | Abbott Gmbh & Co. Kg | Herstellung von festen Dosierungsformen unter Verwendung eines vernetzten nichtthermoplastischen Trägers |
| WO2004052310A2 (en) * | 2002-12-11 | 2004-06-24 | Bristol-Myers Squibb Company | Process and intermediates for synthesis entecavir |
| JP3841804B2 (ja) | 2003-10-15 | 2006-11-08 | 富士化学工業株式会社 | 口腔内速崩壊性錠剤用の組成物 |
| US8349361B2 (en) | 2003-10-15 | 2013-01-08 | Fuji Chemical Industry Co., Ltd. | Composition for rapid disintegrating tablet in oral cavity |
| RU2253451C1 (ru) * | 2004-03-15 | 2005-06-10 | Общество с ограниченной ответственностью "ЮНАЛ" | Антиаллергическое средство |
| JP4880591B2 (ja) | 2004-06-04 | 2012-02-22 | テバ ファーマシューティカル インダストリーズ リミティド | イルベサルタンを含む医薬組成物 |
| JP3996626B2 (ja) * | 2004-06-22 | 2007-10-24 | 塩野義製薬株式会社 | 口腔内速崩壊錠 |
| KR101483297B1 (ko) * | 2005-03-24 | 2015-01-21 | 다이이찌 산쿄 가부시키가이샤 | 의약용 조성물 |
| TWI383809B (zh) * | 2005-06-29 | 2013-02-01 | Otsuka Pharma Co Ltd | 含有西洛他唑（ｃｉｌｏｓｔａｚｏｌ）之口腔崩解粉末 |
| DE602006004694D1 (de) | 2006-01-05 | 2009-02-26 | Teva Pharma | Feuchtgranulierungsmethode zur Herstellung pharmazeutischer Aripiprazolzusammensetzungen |
| CN101351193A (zh) * | 2006-01-05 | 2009-01-21 | 特瓦制药工业有限公司 | 阿立哌唑的干法制剂 |
| EP1806130B1 (en) * | 2006-01-09 | 2010-03-31 | KRKA, D.D., Novo Mesto | Solid pharmaceutical composition comprising irbesartan |
| NZ572106A (en) * | 2006-03-31 | 2010-12-24 | Rubicon Res Private Ltd | Directly compressible composite for orally disintegrating tablets |
| BRPI0807581A2 (pt) | 2007-02-23 | 2014-07-01 | Gilead Science, Inc. | Moduladores de propriedades farmacocinéticas de produtos terapêuticos |
| CA2682929A1 (en) * | 2007-04-17 | 2008-10-23 | Ratiopharm Gmbh | Pharmaceutical compositions comprising irbesartan |
| CN101677945A (zh) * | 2007-05-08 | 2010-03-24 | 赫尔克里士公司 | 坚固的快速崩解片剂制剂 |
| CN101322709B (zh) * | 2007-06-12 | 2011-03-02 | 成都康弘药业集团股份有限公司 | 一种含有阿立哌唑的药物组合物及其制备方法 |
| SI2296633T1 (sl) | 2008-05-02 | 2015-11-30 | Gilead Sciences, Inc. | Uporaba trdnih nosilnih delcev za izboljšanje predelovalnih sposobnosti farmacevtskega sredstva |
| JP5296456B2 (ja) * | 2008-08-26 | 2013-09-25 | 大日本住友製薬株式会社 | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 |
| US20120004321A1 (en) * | 2009-03-16 | 2012-01-05 | Nipro Corporation | Orally Disintegrating Tablet |
| WO2010146551A2 (en) * | 2009-06-16 | 2010-12-23 | Ranbaxy Laboratories Limited | Orally disintegrating compositions comprising antihypertensive agents |
| CA2773003A1 (en) | 2009-09-15 | 2011-03-24 | Ratiopharm Gmbh | Orally disintegrating pharmaceutical dosage form containing aripiprazole |
| TR201000689A1 (tr) * | 2010-01-29 | 2011-08-22 | Bi̇lgi̇ç Mahmut | Sefprozil içeren katı dozaj formlar. |
| CN102218040A (zh) * | 2010-04-13 | 2011-10-19 | 齐鲁制药有限公司 | 一种阿立哌唑组合物微晶的口腔崩解片及其制备方法 |
| EP2384742A1 (en) | 2010-05-03 | 2011-11-09 | The Jordanian Pharmaceutical Manufacturing Co. | Pharmaceutical excipient, method for its preparation and use thereof |
| DE102010019416A1 (de) * | 2010-05-04 | 2011-11-10 | Stada Arzneimittel Ag | Schmelztablette, umfassend ein Triptan oder ein atypisches Neuroleptikum |
| HU1000278D0 (en) | 2010-05-28 | 2010-07-28 | Egis Gyogyszergyar Nyilvanosan | Novel pharmaceutical use uf silicic acid |
| JP2012121850A (ja) * | 2010-12-09 | 2012-06-28 | Otsuka Pharmaceut Co Ltd | アリピプラゾールの経口速溶性組成物 |
| MX358344B (es) | 2011-03-18 | 2018-08-15 | Alkermes Pharma Ireland Ltd | Composiciones farmaceuticas que comprenden un antipsicotico insoluble en agua y esteres de sorbitan. |
| WO2012127429A2 (en) * | 2011-03-21 | 2012-09-27 | Coloright Ltd. | Systems for custom coloration |
| JP6034377B2 (ja) * | 2011-06-27 | 2016-11-30 | シャンハイ チョンシ ファーマシューティカル コーポレイション | アリピプラゾール医薬製剤及びその調製方法 |
| CN102846564B (zh) * | 2011-06-28 | 2013-10-09 | 南京亿华药业有限公司 | 一种头孢丙烯片及其制法 |
| CN102357086A (zh) * | 2011-11-01 | 2012-02-22 | 上海理工大学 | 一种头孢丙烯口腔崩解片 |
| MX2014007933A (es) * | 2011-12-26 | 2014-07-30 | Novartis Ag | Comprimidos y agentes recubiertos en seco. |
| AU2013235523B9 (en) | 2012-03-19 | 2018-01-04 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising glycerol esters |
| NZ630428A (en) | 2012-03-19 | 2017-02-24 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions comprising benzyl alcohol |
| EP2827868B8 (en) | 2012-03-19 | 2019-12-18 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
| WO2013175508A2 (en) | 2012-05-24 | 2013-11-28 | Medreich Limited | Stable pharmaceutical composition of aripiprazole |
| CA2779052A1 (en) * | 2012-05-31 | 2013-11-30 | Pharmascience Inc. | Pharmaceutical composition of entecavir and process of manufacturing |
| KR101571670B1 (ko) | 2012-08-08 | 2015-11-25 | 주식회사 씨엠지제약 | 아리피프라졸을 포함하는 경구용 속용 필름 제제 |
| WO2014030172A2 (en) * | 2012-08-23 | 2014-02-27 | Hetero Research Foundation | Pharmaceutical formulations of rufinamide |
| WO2014080285A2 (en) | 2012-09-19 | 2014-05-30 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
| CN102885790B (zh) * | 2012-09-20 | 2013-12-25 | 中国人民解放军第三〇二医院 | 恩替卡韦分散片及其制备方法 |
| ES2625613T3 (es) | 2013-04-30 | 2017-07-20 | Otsuka Pharmaceutical Co., Ltd. | Preparación sólida oral que comprende aripiprazol y método para producir una preparación sólida oral que comprende aripiprazol |
| JP5714652B2 (ja) * | 2013-06-13 | 2015-05-07 | 大日本住友製薬株式会社 | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 |
| EP3065700A1 (en) | 2013-11-07 | 2016-09-14 | Synthon B.V. | Orodispersible pharmaceutical compositions comprising aripiprazole |
| CN110368360A (zh) | 2014-03-20 | 2019-10-25 | 奥克梅斯制药爱尔兰有限公司 | 具有增加的注射速度的阿立哌唑制剂 |
| JP5978335B2 (ja) * | 2015-03-11 | 2016-08-24 | 大日本住友製薬株式会社 | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 |
| KR20160139704A (ko) | 2015-05-28 | 2016-12-07 | 주식회사 씨엠지제약 | 아리피프라졸을 포함하는 경구용 속용 필름 제제, 및 이의 제조방법 |
| JP2015172084A (ja) * | 2015-07-06 | 2015-10-01 | 大塚製薬株式会社 | アリピプラゾールの経口速溶性組成物 |
| US9855227B2 (en) | 2015-12-18 | 2018-01-02 | The Procter & Gamble Company | Quick dissolving diphenhydramine oral dosage form |
| TR201617675A2 (tr) | 2016-12-02 | 2018-06-21 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Ari̇pi̇prazole monohi̇drat formülasyonlarinin ağizda dağilan tablet formu |
| JP6572257B2 (ja) * | 2017-05-16 | 2019-09-04 | 大塚製薬株式会社 | アリピプラゾールの経口速溶性組成物 |
| JP2017141299A (ja) * | 2017-05-24 | 2017-08-17 | 大日本住友製薬株式会社 | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 |
| WO2019173230A1 (en) | 2018-03-05 | 2019-09-12 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| JP2018168185A (ja) * | 2018-07-05 | 2018-11-01 | 大日本住友製薬株式会社 | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 |
| JP2019203031A (ja) * | 2019-09-06 | 2019-11-28 | 大日本住友製薬株式会社 | 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠 |
| RU2732291C1 (ru) * | 2020-02-13 | 2020-09-15 | Открытое акционерное общество "Фармстандарт-Лексредства" (ОАО "Фармстандарт-Лексредства") | Лекарственный препарат на основе травы алтея лекарственного для лечения простудных и острых респираторных заболеваний |
| GB2617603B (en) * | 2022-04-13 | 2025-06-04 | Univ Brunel | Compositions for preventing and treating infection |
| CN115227661B (zh) * | 2022-09-22 | 2022-12-13 | 北京惠之衡生物科技有限公司 | 一种利格列汀片及其制备方法 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1912354B2 (de) * | 1969-03-12 | 1972-04-13 | Reimbold & Strick, 5000 Köln-Kalk | Synthetisches kristallines calciumsilikat und verfahren zu seiner herstellung |
| US3622677A (en) * | 1969-07-07 | 1971-11-23 | Staley Mfg Co A E | Compressed tablets containing compacted starch as binder-disintegrant ingredient |
| FR2234244B1 (sl) * | 1973-06-20 | 1978-02-17 | Rech Geolog Miniere | |
| DE2556561C2 (de) | 1975-12-16 | 1983-04-14 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren zur Herstellung von porösen Tabletten |
| DE2845326C2 (de) * | 1978-10-18 | 1985-05-23 | Beiersdorf Ag, 2000 Hamburg | Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung |
| DE2849494A1 (de) | 1978-11-15 | 1980-05-29 | Voss Gunter M | Verfahren zur herstellung von arzneimittel-formlingen |
| US4327080A (en) * | 1981-07-13 | 1982-04-27 | E. R. Squibb & Sons, Inc. | Novel Bendroflumethiazide formulations and method |
| JPS59106473A (ja) * | 1982-12-10 | 1984-06-20 | Nippon Shinyaku Co Ltd | トリアジン誘導体 |
| ZA87279B (en) | 1986-01-17 | 1987-09-30 | Chugai Pharmaceutical Co Ltd | Method for production of stable nicorandil preparation |
| WO1987005804A1 (en) * | 1986-04-01 | 1987-10-08 | The Upjohn Company | Methylprednisolone/sodium carboxymethyl starch tablet composition |
| SE8601624D0 (sv) | 1986-04-11 | 1986-04-11 | Haessle Ab | New pharmaceutical preparations |
| US5032552A (en) * | 1988-07-04 | 1991-07-16 | Tdk Corporation | Biomedical material |
| US5006528A (en) * | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| US4906478A (en) * | 1988-12-12 | 1990-03-06 | Valentine Enterprises, Inc. | Simethicone/calcium silicate composition |
| HU203041B (en) | 1989-03-14 | 1991-05-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin |
| JPH06271744A (ja) * | 1993-03-22 | 1994-09-27 | Mizusawa Ind Chem Ltd | ポリアセタール系樹脂用帯電防止剤 |
| US5393472A (en) * | 1993-06-30 | 1995-02-28 | Shaw; John D. | Method of producing wollastonite & ceramic bodies containing wollastonite |
| IL110376A (en) * | 1993-08-02 | 1998-08-16 | Bristol Myers Squibb Co | Pharmaceutical compositions containing ifetroban salts and methods for the preparation thereof |
| WO1995003785A1 (en) * | 1993-08-03 | 1995-02-09 | Warner-Lambert Company | Pleasant tasting effervescent cold/allergy medications |
| US5622719A (en) * | 1993-09-10 | 1997-04-22 | Fuisz Technologies Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
| US5895664A (en) * | 1993-09-10 | 1999-04-20 | Fuisz Technologies Ltd. | Process for forming quickly dispersing comestible unit and product therefrom |
| CA2197091A1 (en) * | 1994-08-08 | 1996-02-22 | Fusao Ueda | Triazine derivative and medicine |
| TW318841B (sl) * | 1995-02-17 | 1997-11-01 | Takeda Pharm Industry Co Ltd | |
| US5994348A (en) * | 1995-06-07 | 1999-11-30 | Sanofi | Pharmaceutical compositions containing irbesartan |
| TW442301B (en) * | 1995-06-07 | 2001-06-23 | Sanofi Synthelabo | Pharmaceutical compositions containing irbesartan |
| AU3865595A (en) * | 1995-11-17 | 1997-06-11 | Vrije Universiteit Brussel | Inorganic resin compositions, their preparation and use thereof |
| TW430561B (en) * | 1995-12-20 | 2001-04-21 | Gea Farmaceutisk Fabrik As | Rapid release tablet composition comprising tolfenamic acid or a pharmaceutically acceptable salt thereof as active ingredient and a method of preparing such tablet |
| JP3180350B2 (ja) * | 1996-02-29 | 2001-06-25 | 藤沢薬品工業株式会社 | β―ラクタム系抗生物質含有錠剤およびその製造法 |
| GB9613470D0 (en) * | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| ATE291930T1 (de) * | 1996-07-12 | 2005-04-15 | Daiichi Seiyaku Co | Schnell zerfallende, druckgeformte materialien sowie prozess zu deren herstellung |
| CA2258917A1 (en) * | 1996-07-23 | 1998-01-29 | Fmc Corporation | Disintegrant composition for dispersible solids |
| JPH10114655A (ja) | 1996-10-09 | 1998-05-06 | Kyowa Hakko Kogyo Co Ltd | 固形製剤 |
| JPH10182436A (ja) | 1996-10-31 | 1998-07-07 | Takeda Chem Ind Ltd | 固形医薬製剤 |
| AUPO446397A0 (en) | 1997-01-07 | 1997-01-30 | Rees Equipment Pty Ltd | Agricultural equipment direction control |
| US6024981A (en) * | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
| TW527195B (en) * | 1997-10-09 | 2003-04-11 | Ssp Co Ltd | Fast-soluble solid pharmaceutical combinations |
| JPH11152220A (ja) * | 1997-11-19 | 1999-06-08 | Daiichi Yakuhin Kogyo Kk | 脂溶性薬物を含有した丸剤の製造方法 |
| HUP0100469A2 (hu) * | 1997-12-19 | 2001-08-28 | Smithkline Beecham Corporation | Eljárás harapással diszpergálható tabletták előállítására |
| US5914128A (en) * | 1997-12-22 | 1999-06-22 | Schering Corporation | Orally administrable solid dosage form |
| ATE219658T1 (de) | 1998-03-06 | 2002-07-15 | Eurand Int | Schnell zerfallende tablette |
| JP4027535B2 (ja) | 1998-05-26 | 2007-12-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 脂溶性薬物を含有した粉末 |
| CO5070643A1 (es) * | 1998-05-27 | 2001-08-28 | Merck & Co Inc | Formulacion en tabletas comprimidas |
| JP2000119014A (ja) | 1998-08-12 | 2000-04-25 | Fuji Chem Ind Co Ltd | 無晶形ケイ酸アルミン酸カルシウム複合酸化物及びその製造方法並びに制酸剤 |
| JP2000086537A (ja) | 1998-09-11 | 2000-03-28 | Fuji Chem Ind Co Ltd | 無機化合物糖類組成物、賦形剤、速崩壊性圧縮成型物及びその製造方法 |
| US6133378A (en) * | 1998-11-20 | 2000-10-17 | Bridgestone/Firestone, Inc. | EPDM-based roofing shingle compositions |
| GB9914936D0 (en) | 1999-06-26 | 1999-08-25 | Cerestar Holding Bv | Directly compressible starch as enhancer of properties of excipients when used as binder and disintegrant for compression tablets |
| CA2311734C (en) | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
| US20020076437A1 (en) * | 2000-04-12 | 2002-06-20 | Sanjeev Kothari | Flashmelt oral dosage formulation |
| CN1261783C (zh) | 2001-06-29 | 2006-06-28 | 美莎诺普有限公司 | 优化连接器特征的方法 |
| TWI324074B (en) * | 2001-10-09 | 2010-05-01 | Bristol Myers Squibb Co | Flashmelt oral dosage formulation |
| US6610266B2 (en) * | 2001-11-28 | 2003-08-26 | Michael C. Withiam | Calcium metasilicates and methods for making |
-
2000
- 2000-06-15 CA CA2311734A patent/CA2311734C/en not_active Expired - Lifetime
- 2000-06-16 AR ARP000103004A patent/AR024384A1/es active IP Right Grant
- 2000-06-17 TW TW089111962A patent/TWI262799B/zh not_active IP Right Cessation
- 2000-06-19 HU HU0002316A patent/HU228864B1/hu unknown
- 2000-06-20 NZ NZ505302A patent/NZ505302A/en not_active IP Right Cessation
- 2000-06-20 NO NO20003196A patent/NO330270B1/no not_active IP Right Cessation
- 2000-06-20 IL IL136901A patent/IL136901A/en active IP Right Grant
- 2000-06-21 ZA ZA200003121A patent/ZA200003121B/xx unknown
- 2000-06-22 MY MYPI20002810A patent/MY125766A/en unknown
- 2000-06-23 SK SK973-2000A patent/SK286368B6/sk not_active IP Right Cessation
- 2000-06-23 CZ CZ20002391A patent/CZ299145B6/cs not_active IP Right Cessation
- 2000-06-26 EG EG20000818A patent/EG23943A/xx active
- 2000-06-27 ES ES00113571T patent/ES2265836T3/es not_active Expired - Lifetime
- 2000-06-27 DK DK00113571T patent/DK1145711T3/da active
- 2000-06-27 EP EP05010256A patent/EP1566174A3/en not_active Ceased
- 2000-06-27 DE DE60028536T patent/DE60028536T2/de not_active Expired - Lifetime
- 2000-06-27 EP EP00113571A patent/EP1145711B1/en not_active Expired - Lifetime
- 2000-06-27 AT AT00113571T patent/ATE328584T1/de active
- 2000-06-27 PT PT00113571T patent/PT1145711E/pt unknown
- 2000-06-28 JP JP2000194976A patent/JP3773763B2/ja not_active Expired - Lifetime
- 2000-06-29 AU AU43733/00A patent/AU752214B2/en not_active Expired
- 2000-06-30 ID IDP20000548D patent/ID29837A/id unknown
- 2000-07-03 RO ROA200000690A patent/RO118563B1/ro unknown
- 2000-07-05 PE PE2000000674A patent/PE20010298A1/es not_active Application Discontinuation
- 2000-07-06 TR TR2000/01810A patent/TR200001810A3/tr unknown
- 2000-07-06 IN IN625MU2000 patent/IN188856B/en unknown
- 2000-07-11 LT LT2000064A patent/LT4896B/lt not_active IP Right Cessation
- 2000-07-13 KR KR10-2000-0040080A patent/KR100477293B1/ko not_active Expired - Lifetime
- 2000-07-14 PL PL341466A patent/PL200409B1/pl unknown
- 2000-07-17 CN CNB001201077A patent/CN100353933C/zh not_active Expired - Lifetime
- 2000-07-18 GE GEAP20005473A patent/GEP20022851B/en unknown
- 2000-07-21 LV LVP-00-97A patent/LV12731B/en unknown
- 2000-07-26 BR BR0003158-5A patent/BR0003158A/pt not_active Application Discontinuation
- 2000-08-08 CO CO00059228A patent/CO5190672A1/es active IP Right Grant
- 2000-08-14 SI SI200000187A patent/SI20511B/sl active Search and Examination
- 2000-08-15 BG BG104693A patent/BG65007B1/bg unknown
- 2000-08-15 SG SG200004496A patent/SG108230A1/en unknown
- 2000-08-15 SG SG200302609A patent/SG117445A1/en unknown
- 2000-08-21 UY UY26306A patent/UY26306A1/es not_active IP Right Cessation
- 2000-09-01 EE EEP200000497A patent/EE04331B1/xx unknown
- 2000-09-07 RU RU2000123156/14A patent/RU2201216C2/ru active
- 2000-10-12 UA UA2000105783A patent/UA63993C2/uk unknown
-
2002
- 2002-02-18 HK HK02101145.0A patent/HK1039572B/en not_active IP Right Cessation
-
2006
- 2006-08-28 CY CY20061101204T patent/CY1105170T1/el unknown
-
2009
- 2009-09-14 US US12/558,813 patent/US20100016448A1/en not_active Abandoned
-
2011
- 2011-05-16 US US13/108,193 patent/US8518421B2/en not_active Expired - Fee Related
-
2013
- 2013-07-10 US US13/938,706 patent/US9358207B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI20511B (sl) | Izdelovanje trenutno raztopljivega peroralnega odmerka | |
| KR102803917B1 (ko) | 루카파립의 고 용량 강도 정제 | |
| JP6009967B2 (ja) | 固形製剤 | |
| HRP20100674T1 (hr) | Farmaceutski pripravak koji sadrzi omega-karboksiaril supstituirani difenil ureu za lijecenje raka | |
| US3632778A (en) | Tablets containing l-dopa | |
| KR101788350B1 (ko) | 아카보스를 함유하는 경구 붕해 정제 | |
| KR101230178B1 (ko) | 골다공증 예방 또는 치료용 조성물 및 이의 제조방법 | |
| TW202019430A (zh) | 含有難溶性鹼性藥劑的醫藥組成物 | |
| AU774801B2 (en) | Low-dose tablets and preparation method | |
| JP2011246428A (ja) | 口腔内崩壊型医薬品及びその製造方法 | |
| JP5428619B2 (ja) | 生薬含有錠剤 | |
| JP4519444B2 (ja) | 口腔内崩壊錠 | |
| RU2183119C1 (ru) | Фармацевтическая композиция, обладающая спазмолитической активностью, способ ее получения | |
| JP4719899B2 (ja) | 口腔内速崩壊性錠剤 | |
| RU2190407C1 (ru) | Способ получения противовирусного средства | |
| US3784708A (en) | Directly compressible monocalcium phosphate | |
| JP2005502729A (ja) | 植物抽出物から錠剤を製造するための方法 | |
| KR19990077229A (ko) | 고함량 팜시클로비르 정제 | |
| CN115212176B (zh) | 泽布替尼缓释片剂 | |
| JP3637968B1 (ja) | 胃内崩壊性錠剤 | |
| JP4573542B2 (ja) | ビタミンｂ１誘導体組成物 | |
| JP6838632B2 (ja) | 固形製剤 | |
| JPH05221853A (ja) | 崩壊性良好な生薬類含有造粒物 | |
| US20050019397A1 (en) | Cellulosic fiber containing composition | |
| KR20160140567A (ko) | 오셀타미비어 유리염기를 포함하는 약학 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| IF | Valid on the event date | ||
| OU02 | Decision according to article 73(2) ipa 1992, publication of decision on partial fulfilment of the invention and change of patent claims |
Effective date: 20080703 |